☰

Erika Vacchelli - Publications

Affiliations: 
University Paris 11 
Area:
Breast cancer, Signature, Non small cell lung cancer, Head and neck carcinoma, Immunogenic cell death, ECE1, PZP, Rs2241880, Rs3751143, Rs4986790, Cancer
Tree Info Similar researchers PubMed Report error

92 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Le Naour J, Montégut L, Pan Y, Scuderi SA, Cordier P, Joseph A, Sauvat A, Iebba V, Paillet J, Ferrere G, Brechard L, Mulot C, Dubourg G, Zitvogel L, Pol JG, ... Vacchelli E, et al. Formyl peptide receptor-1 (FPR1) represses intestinal oncogenesis. Oncoimmunology. 12: 2237354. PMID 37492227 DOI: 10.1080/2162402X.2023.2237354  0.426
2023 Carbonnier V, Le Naour J, Bachelot T, Vacchelli E, André F, Delaloge S, Kroemer G. Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancer. Oncoimmunology. 12: 2189823. PMID 36970071 DOI: 10.1080/2162402X.2023.2189823  0.339
2022 Le Naour J, Sztupinszki Z, Carbonnier V, Casiraghi O, Marty V, Galluzzi L, Szallasi Z, Kroemer G, Vacchelli E. A loss-of-function polymorphism in compromises therapeutic outcome in head and neck carcinoma patients. Oncoimmunology. 11: 2059878. PMID 35481288 DOI: 10.1080/2162402X.2022.2059878  0.607
2021 Sztupinszki Z, Le Naour J, Vacchelli E, Laurent-Puig P, Delaloge S, Szallasi Z, Kroemer G. A major genetic accelerator of cancer diagnosis: rs867228 in FPR1. Oncoimmunology. 10: 1859064. PMID 33489470 DOI: 10.1080/2162402X.2020.1859064  0.318
2020 Petrazzuolo A, Le Naour J, Vacchelli E, Gaussem P, Ellouze S, Jourdi G, Solary E, Fontenay M, Smadja DM, Kroemer G. No impact of cancer and plague-relevant polymorphisms on COVID-19. Oncoimmunology. 9: 1857112. PMID 33344044 DOI: 10.1080/2162402X.2020.1857112  0.34
2020 Castoldi F, Humeau J, Martins I, Lachkar S, Loew D, Dingli F, Durand S, Enot D, Bossut N, Chery A, Aprahamian F, Demont Y, Opolon P, Signolle N, Sauvat A, ... ... Vacchelli E, et al. Autophagy-mediated metabolic effects of aspirin. Cell Death Discovery. 6: 129. PMID 33298861 DOI: 10.1038/s41420-020-00365-0  0.775
2020 Le Naour J, Liu P, Zhao L, Adjemian S, Sztupinszki Z, Taieb J, Mulot C, Silvin A, Dutertre CA, Ginhoux F, Sauvat A, Cerrato G, Castoldi F, Martins I, Stoll G, ... ... Vacchelli E, et al. A TLR3 ligand reestablishes chemotherapeutic responses in the context of FPR1 deficiency. Cancer Discovery. PMID 33046534 DOI: 10.1158/2159-8290.CD-20-0465  0.83
2020 Frega G, Wu Q, Le Naour J, Vacchelli E, Galluzzi L, Kroemer G, Kepp O. Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. Oncoimmunology. 9: 1796002. PMID 32934889 DOI: 10.1080/2162402X.2020.1796002  0.626
2020 Le Naour J, Galluzzi L, Zitvogel L, Kroemer G, Vacchelli E. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology. 9: 1777625. PMID 32934882 DOI: 10.1080/2162402X.2020.1777625  0.638
2020 Le Naour J, Zitvogel L, Galluzzi L, Vacchelli E, Kroemer G. Trial watch: STING agonists in cancer therapy. Oncoimmunology. 9: 1777624. PMID 32934881 DOI: 10.1080/2162402X.2020.1777624  0.634
2020 Le Naour J, Galluzzi L, Zitvogel L, Kroemer G, Vacchelli E. Trial watch: TLR3 agonists in cancer therapy. Oncoimmunology. 9: 1771143. PMID 32934877 DOI: 10.1080/2162402X.2020.1771143  0.634
2020 Vacchelli E, Le Naour J, Kroemer G. The ambiguous role of FPR1 in immunity and inflammation. Oncoimmunology. 9: 1760061. PMID 32391192 DOI: 10.1080/2162402X.2020.1760061  0.446
2020 Castoldi F, Hyvönen MT, Durand S, Aprahamian F, Sauvat A, Malik SA, Baracco EE, Vacchelli E, Opolon P, Signolle N, Lefevre D, Bossut N, Eisenberg T, Dammbrueck C, Pendl T, et al. Chemical activation of SAT1 corrects diet-induced metabolic syndrome. Cell Death and Differentiation. PMID 32376874 DOI: 10.1038/S41418-020-0550-Z  0.779
2020 Comes MC, Filippi J, Mencattini A, Casti P, Cerrato G, Sauvat A, Vacchelli E, Ninno AD, Giuseppe DD, D’Orazio M, Mattei F, Schiavoni G, Businaro L, Natale CD, Kroemer G, et al. Multi-scale generative adversarial network for improved evaluation of cell–cell interactions observed in organ-on-chip experiments Neural Computing and Applications. 1-19. DOI: 10.1007/S00521-020-05226-6  0.402
2019 Baracco EE, Stoll G, Van Endert P, Zitvogel L, Vacchelli E, Kroemer G. Contribution of annexin A1 to anticancer immunosurveillance. Oncoimmunology. 8: e1647760. PMID 32923172 DOI: 10.1080/2162402X.2019.1647760  0.573
2019 Lévesque S, Le Naour J, Pietrocola F, Paillet J, Kremer M, Castoldi F, Baracco EE, Wang Y, Vacchelli E, Stoll G, Jolly A, De La Grange P, Zitvogel L, Kroemer G, Pol JG. A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. Oncoimmunology. 8: e1657375. PMID 31646107 DOI: 10.1080/2162402X.2019.1657375  0.712
2019 Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, Pfirschke C, Engblom C, Rickelt S, Yamazaki T, Iribarren K, Senovilla L, Bezu L, Vacchelli E, Sica V, Melis A, et al. Author Correction: Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nature Communications. 10: 1883. PMID 30996258 DOI: 10.1038/S41467-019-09838-Y  0.669
2019 Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, Pfirschke C, Engblom C, Rickelt S, Yamazaki T, Iribarren K, Senovilla L, Bezu L, Vacchelli E, Sica V, Melis A, et al. Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nature Communications. 10: 1486. PMID 30940805 DOI: 10.1038/S41467-019-09415-3  0.729
2019 Castoldi F, Vacchelli E, Zitvogel L, Maiuri MC, Pietrocola F, Kroemer G. Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy. Oncoimmunology. 8: e1498285. PMID 30546941 DOI: 10.1080/2162402X.2018.1498285  0.797
2018 Enot DP, Vacchelli E, Jacquelot N, Zitvogel L, Kroemer G. TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves. Oncoimmunology. 7: e1462431. PMID 30228932 DOI: 10.1080/2162402X.2018.1462431  0.351
2017 Biselli E, Agliari E, Barra A, Bertani FR, Gerardino A, De Ninno A, Mencattini A, Di Giuseppe D, Mattei F, Schiavoni G, Lucarini V, Vacchelli E, Kroemer G, Di Natale C, Martinelli E, et al. Organs on chip approach: a tool to evaluate cancer -immune cells interactions. Scientific Reports. 7: 12737. PMID 28986543 DOI: 10.1038/S41598-017-13070-3  0.528
2016 Semeraro M, Adam J, Stoll G, Louvet E, Chaba K, Poirier-Colame V, Sauvat A, Senovilla L, Vacchelli E, Bloy N, Humeau J, Buque A, Kepp O, Zitvogel L, André F, et al. The ratio of CD8(+)/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ. Oncoimmunology. 5: e1218106. PMID 27853639 DOI: 10.1080/2162402X.2016.1218106  0.43
2016 Vacchelli E, Bloy N, Aranda F, Buqué A, Cremer I, Demaria S, Eggermont A, Formenti SC, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, et al. Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology. 5: e1214790. PMID 27757313 DOI: 10.1080/2162402X.2016.1214790  0.637
2016 Pietrocola F, Pol J, Vacchelli E, Baracco EE, Levesque S, Castoldi F, Maiuri MC, Madeo F, Kroemer G. Autophagy induction for the treatment of cancer. Autophagy. 12: 1962-1964. PMID 27532519 DOI: 10.1080/15548627.2016.1214778  0.784
2016 Yang H, Ma Y, Chen G, Zhou H, Yamazaki T, Klein C, Pietrocola F, Vacchelli E, Souquere S, Sauvat A, Zitvogel L, Kepp O, Kroemer G. Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. Oncoimmunology. 5: e1149673. PMID 27471616 DOI: 10.1080/2162402X.2016.1149673  0.794
2016 Baracco EE, Pietrocola F, Buqué A, Bloy N, Senovilla L, Zitvogel L, Vacchelli E, Kroemer G. Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. Oncoimmunology. 5: e1139275. PMID 27471610 DOI: 10.1080/2162402X.2016.1139275  0.719
2016 Vacchelli E, Ma Y, Baracco EE, Zitvogel L, Kroemer G. Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: Formyl peptide receptor-1. Oncoimmunology. 5: e1118600. PMID 27467929 DOI: 10.1080/2162402X.2015.1118600  0.506
2016 Pietrocola F, Pol J, Vacchelli E, Rao S, Enot DP, Baracco EE, Levesque S, Castoldi F, Jacquelot N, Yamazaki T, Senovilla L, Marino G, Aranda F, Durand S, Sica V, et al. Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. Cancer Cell. 30: 147-60. PMID 27411589 DOI: 10.1016/J.Ccell.2016.05.016  0.806
2016 Vacchelli E, Enot DP, Pietrocola F, Zitvogel L, Kroemer G. Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant Chemotherapy. Cancer Research. 76: 3122-6. PMID 27197163 DOI: 10.1158/0008-5472.Can-16-0294  0.745
2016 Vacchelli E, Aranda F, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch-Immunostimulation with cytokines in cancer therapy. Oncoimmunology. 5: e1115942. PMID 27057468 DOI: 10.1080/2162402X.2015.1115942  0.656
2016 Vacchelli E, Semeraro M, Adam J, Dartigues P, Zitvogel L, Kroemer G. Immunosurveillance in esophageal carcinoma: The decisive impact of regulatory T cells. Oncoimmunology. 5: e1064581. PMID 27057430 DOI: 10.1080/2162402X.2015.1064581  0.502
2015 Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, Coosemans A, Coulie PG, De Ruysscher D, Dini L, de Witte P, ... ... Vacchelli E, et al. Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Frontiers in Immunology. 6: 588. PMID 26635802 DOI: 10.3389/Fimmu.2015.00588  0.705
2015 Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F, Yang H, Adjemian S, Chaba K, Semeraro M, Signore M, De Ninno A, Lucarini V, Peschiaroli F, Businaro L, et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science (New York, N.Y.). PMID 26516201 DOI: 10.1126/Science.Aad0779  0.849
2015 Vacchelli E, Sistigu A, Yamazaki T, Vitale I, Zitvogel L, Kroemer G. Autocrine signaling of type 1 interferons in successful anticancer chemotherapy. Oncoimmunology. 4: e988042. PMID 26405588 DOI: 10.4161/2162402X.2014.988042  0.592
2015 Vacchelli E, Semeraro M, Enot DP, Chaba K, Poirier Colame V, Dartigues P, Perier A, Villa I, Rusakiewicz S, Gronnier C, Goéré D, Mariette C, Zitvogel L, Kroemer G. Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy. Oncotarget. 6: 20840-50. PMID 26369701 DOI: 10.18632/Oncotarget.4428  0.568
2015 Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology. 4: e1008866. PMID 26137404 DOI: 10.1080/2162402X.2015.1008866  0.672
2015 Enot DP, Niso-Santano M, Durand S, Chery A, Pietrocola F, Vacchelli E, Madeo F, Galluzzi L, Kroemer G. Metabolomic analyses reveal that anti-aging metabolites are depleted by palmitate but increased by oleate in vivo. Cell Cycle (Georgetown, Tex.). 14: 2399-407. PMID 26098646 DOI: 10.1080/15384101.2015.1064206  0.7
2015 Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 4: e985940. PMID 25949870 DOI: 10.4161/2162402X.2014.985940  0.66
2014 Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 3: e955691. PMID 25941621 DOI: 10.4161/21624011.2014.955691  0.834
2014 Vacchelli E, Aranda F, Eggermont A, Sautès-Fridman C, Tartour E, Kennedy EP, Platten M, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology. 3: e957994. PMID 25941578 DOI: 10.4161/21624011.2014.957994  0.634
2014 Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, et al. Classification of current anticancer immunotherapies. Oncotarget. 5: 12472-508. PMID 25537519 DOI: 10.18632/Oncotarget.2998  0.642
2014 Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nature Medicine. 20: 1301-9. PMID 25344738 DOI: 10.1038/Nm.3708  0.491
2014 Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Henrik Ter Meulen J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology. 3: e29179. PMID 25083332 DOI: 10.4161/Onci.29179  0.636
2014 Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Immunostimulatory cytokines in cancer therapy. Oncoimmunology. 3: e29030. PMID 25083328 DOI: 10.4161/Onci.29030  0.672
2014 Sukkurwala AQ, Adjemian S, Senovilla L, Michaud M, Spaggiari S, Vacchelli E, Baracco EE, Galluzzi L, Zitvogel L, Kepp O, Kroemer G. Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. Oncoimmunology. 3: e28473. PMID 25050214 DOI: 10.4161/Onci.28473  0.837
2014 Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Hervé Fridman W, Cremer I, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology. 3: e28344. PMID 25050207 DOI: 10.4161/onci.28344  0.59
2014 Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology. 3: e27878. PMID 24800173 DOI: 10.4161/Onci.27878  0.712
2014 Pietrocola F, Malik SA, Mariño G, Vacchelli E, Senovilla L, Chaba K, Niso-Santano M, Maiuri MC, Madeo F, Kroemer G. Coffee induces autophagy in vivo. Cell Cycle (Georgetown, Tex.). 13: 1987-94. PMID 24769862 DOI: 10.4161/Cc.28929  0.793
2014 Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology. 3: e27297. PMID 24701370 DOI: 10.4161/Onci.27297  0.623
2014 Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology. 3: e27048. PMID 24605265 DOI: 10.4161/Onci.27048  0.632
2014 Mariño G, Pietrocola F, Eisenberg T, Kong Y, Malik SA, Andryushkova A, Schroeder S, Pendl T, Harger A, Niso-Santano M, Zamzami N, Scoazec M, Durand S, Enot DP, Fernández ÁF, ... ... Vacchelli E, et al. Regulation of autophagy by cytosolic acetyl-coenzyme A. Molecular Cell. 53: 710-25. PMID 24560926 DOI: 10.1016/J.Molcel.2014.01.016  0.795
2014 Sukkurwala AQ, Martins I, Wang Y, Schlemmer F, Ruckenstuhl C, Durchschlag M, Michaud M, Senovilla L, Sistigu A, Ma Y, Vacchelli E, Sulpice E, Gidrol X, Zitvogel L, Madeo F, et al. Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. Cell Death and Differentiation. 21: 59-68. PMID 23787997 DOI: 10.1038/Cdd.2013.73  0.828
2013 Aranda F, Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology. 2: e26621. PMID 24498550 DOI: 10.4161/onci.26621  0.588
2013 Semeraro M, Vacchelli E, Eggermont A, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology. 2: e26494. PMID 24482747 DOI: 10.4161/Onci.26494  0.627
2013 Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology. 2: e25595. PMID 24319634 DOI: 10.4161/Onci.25595  0.706
2013 Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fučíková J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology. 2: e25771. PMID 24286020 DOI: 10.4161/onci.25771  0.591
2013 Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2: e25238. PMID 24083080 DOI: 10.4161/Onci.25238  0.608
2013 Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory cytokines. Oncoimmunology. 2: e24850. PMID 24073369 DOI: 10.4161/Onci.24850  0.662
2013 Vacchelli E, Prada N, Kepp O, Galluzzi L. Current trends of anticancer immunochemotherapy. Oncoimmunology. 2: e25396. PMID 23894726 DOI: 10.4161/Onci.25396  0.513
2013 Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology. 2: e24612. PMID 23894720 DOI: 10.4161/onci.24612  0.577
2013 Ma Y, Adjemian S, Yang H, Catani JP, Hannani D, Martins I, Michaud M, Kepp O, Sukkurwala AQ, Vacchelli E, Galluzzi L, Zitvogel L, Kroemer G. ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. Oncoimmunology. 2: e24568. PMID 23894718 DOI: 10.4161/Onci.24568  0.809
2013 Kepp O, Menger L, Vacchelli E, Locher C, Adjemian S, Yamazaki T, Martins I, Sukkurwala AQ, Michaud M, Senovilla L, Galluzzi L, Kroemer G, Zitvogel L. Crosstalk between ER stress and immunogenic cell death. Cytokine & Growth Factor Reviews. 24: 311-8. PMID 23787159 DOI: 10.1016/J.Cytogfr.2013.05.001  0.805
2013 Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology. 2: e24238. PMID 23762803 DOI: 10.4161/Onci.24238  0.669
2013 Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology. 2: e23803. PMID 23734328 DOI: 10.4161/onci.23803  0.56
2013 Martins I, Kepp O, Menger L, Michaud M, Adjemian S, Sukkurwala AQ, Vacchelli E, Galluzzi L, Kroemer G. Fluorescent biosensors for the detection of HMGB1 release. Methods in Molecular Biology (Clifton, N.J.). 1004: 43-56. PMID 23733568 DOI: 10.1007/978-1-62703-383-1_4  0.813
2013 Pietrocola F, Izzo V, Niso-Santano M, Vacchelli E, Galluzzi L, Maiuri MC, Kroemer G. Regulation of autophagy by stress-responsive transcription factors. Seminars in Cancer Biology. 23: 310-22. PMID 23726895 DOI: 10.1016/J.Semcancer.2013.05.008  0.735
2013 Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2: e23510. PMID 23687621 DOI: 10.4161/onci.23510  0.644
2013 Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, Martins I, Schlemmer F, Michaud M, Kepp O, Sukkurwala AQ, ... ... Vacchelli E, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 38: 729-41. PMID 23562161 DOI: 10.1016/J.Immuni.2013.03.003  0.834
2013 Menger L, Vacchelli E, Kepp O, Eggermont A, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Cardiac glycosides and cancer therapy. Oncoimmunology. 2: e23082. PMID 23525565 DOI: 10.4161/Onci.23082  0.783
2013 Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology. 2: e22789. PMID 23482847 DOI: 10.4161/onci.22789  0.592
2013 Galluzzi L, Vacchelli E, Michels J, Garcia P, Kepp O, Senovilla L, Vitale I, Kroemer G. Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses. Oncogene. 32: 4995-5004. PMID 23334322 DOI: 10.1038/Onc.2012.623  0.751
2013 Galluzzi L, Marsili S, Vitale I, Senovilla L, Michels J, Garcia P, Vacchelli E, Chatelut E, Castedo M, Kroemer G. Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. Cell Cycle (Georgetown, Tex.). 12: 417-21. PMID 23287530 DOI: 10.4161/Cc.23275  0.771
2012 Kepp O, Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Sukkurwala AQ, Michaud M, Galluzzi L, Zitvogel L, Kroemer G. Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects. Oncoimmunology. 1: 1640-1642. PMID 23264921 DOI: 10.4161/Onci.21684  0.816
2012 Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology. 1: 1557-1576. PMID 23264902 DOI: 10.4161/Onci.22428  0.617
2012 Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology. 1: 1323-1343. PMID 23243596 DOI: 10.4161/Onci.22009  0.814
2012 Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology. 1: 1111-1134. PMID 23170259 DOI: 10.4161/Onci.21494  0.641
2012 Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology. 1: 894-907. PMID 23162757 DOI: 10.4161/Onci.20931  0.631
2012 Pietrocola F, Mariño G, Lissa D, Vacchelli E, Malik SA, Niso-Santano M, Zamzami N, Galluzzi L, Maiuri MC, Kroemer G. Pro-autophagic polyphenols reduce the acetylation of cytoplasmic proteins. Cell Cycle (Georgetown, Tex.). 11: 3851-60. PMID 23070521 DOI: 10.4161/Cc.22027  0.775
2012 Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 1: 699-716. PMID 22934262 DOI: 10.4161/Onci.20696  0.652
2012 Galluzzi L, Vitale I, Senovilla L, Eisenberg T, Carmona-Gutierrez D, Vacchelli E, Robert T, Ripoche H, Jägemann N, Paccard C, Servant N, Hupé P, Lazar V, Dessen P, Barillot E, et al. Independent transcriptional reprogramming and apoptosis induction by cisplatin. Cell Cycle (Georgetown, Tex.). 11: 3472-80. PMID 22918244 DOI: 10.4161/Cc.21789  0.638
2012 Galluzzi L, Vitale I, Senovilla L, Olaussen KA, Pinna G, Eisenberg T, Goubar A, Martins I, Michels J, Kratassiouk G, Carmona-Gutierrez D, Scoazec M, Vacchelli E, Schlemmer F, Kepp O, et al. Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Reports. 2: 257-69. PMID 22854025 DOI: 10.1016/J.Celrep.2012.06.017  0.774
2012 Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, Yamazaki T, Sukkurwala AQ, Michaud M, Mignot G, Schlemmer F, Sulpice E, Locher C, Gidrol X, Ghiringhelli F, et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Science Translational Medicine. 4: 143ra99. PMID 22814852 DOI: 10.1126/Scitranslmed.3003807  0.821
2012 Vacchelli E, Galluzzi L, Eggermont A, Galon J, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Immunostimulatory cytokines. Oncoimmunology. 1: 493-506. PMID 22754768 DOI: 10.4161/onci.20459  0.629
2012 Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology. 1: 306-315. PMID 22737606 DOI: 10.4161/Onci.19549  0.684
2012 Vacchelli E, Galluzzi L, Rousseau V, Rigoni A, Tesniere A, Delahaye N, Schlemmer FD, Menger L, Sukkurwala AQ, Adjemian S, Martins I, Michaud M, Dunant A, Kepp O, Brambilla E, et al. Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. Oncoimmunology. 1: 271-278. PMID 22737602 DOI: 10.4161/Onci.18684  0.81
2012 Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Kroemer G. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology. 1: 179-188. PMID 22720239 DOI: 10.4161/onci.1.2.19026  0.672
2012 Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zucman-Rossi J, Zitvogel L, Kroemer G. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology. 1: 28-37. PMID 22720209 DOI: 10.4161/Onci.1.1.17938  0.658
2012 Martins I, Michaud M, Sukkurwala AQ, Adjemian S, Ma Y, Shen S, Kepp O, Menger L, Vacchelli E, Galluzzi L, Zitvogel L, Kroemer G. Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. Autophagy. 8: 413-5. PMID 22361584 DOI: 10.4161/Auto.19009  0.84
2011 Galluzzi L, Vitale I, Vacchelli E, Kroemer G. Cell death signaling and anticancer therapy. Frontiers in Oncology. 1: 5. PMID 22655227 DOI: 10.3389/Fonc.2011.00005  0.676
2011 Kroemer G, Adjemian S, Michaud M, Martins I, Kepp O, Sukkurwala AQ, Menger L, Vacchelli E, Ma Y, Zitvogel L. [Contributions of immunogenic cell death to the efficacy of anticancer chemotherapy]. Bulletin Et Memoires De L'Academie Royale De Medecine De Belgique. 166: 130-8; discussion 13. PMID 22375493  0.826
2011 Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, Rello-Varona S, Tailler M, Menger L, Vacchelli E, Galluzzi L, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (New York, N.Y.). 334: 1573-7. PMID 22174255 DOI: 10.1126/Science.1208347  0.832
2010 Galluzzi L, Morselli E, Kepp O, Vitale I, Rigoni A, Vacchelli E, Michaud M, Zischka H, Castedo M, Kroemer G. Mitochondrial gateways to cancer. Molecular Aspects of Medicine. 31: 1-20. PMID 19698742 DOI: 10.1016/J.Mam.2009.08.002  0.77
Show low-probability matches.